Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Placebo Effect01:54

The Placebo Effect

6.1K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.1K
Blinding01:11

Blinding

2.4K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.4K
Blind Procedures02:07

Blind Procedures

10.6K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.6K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

220
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
220

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lithium prescribing in the perinatal period: UK primary care cohort study.

The British journal of psychiatry : the journal of mental science·2026
Same author

Association between gabapentinoid treatment, concurrent use with opioid or benzodiazepine and the risk of drug poisoning: A self-controlled case series study.

PLoS medicine·2026
Same author

Do the pharmacokinetics of statins explain psychiatric symptom improvement from adjunctive statin prescribing in severe mental illness? Three target trial emulation studies.

BMJ mental health·2025
Same author

Temporal relationship between severe mental illness and neurological conditions in a UK primary care cohort.

BMJ mental health·2025
Same author

Exploring risk and protective factors which distinguish suicidal and self-harm behaviours from suicidal and self-harm ideation in young people: A systematic review.

PloS one·2025
Same author

An overview of antipsychotic drug prescribing trends (initiation/prevalence) in UK primary care from 1995 to 2018: analysis of electronic health records from over 790 general practices.

BJPsych open·2025

Related Experiment Video

Updated: Jun 24, 2025

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.5K

Digitally managing depression: A fully remote randomised attention-placebo controlled trial.

Aaron Kandola1,2, Kyra Edwards3, Marie Ae Muller3

  • 1MRC Unit of Lifelong Health and Aging, University College London - UCL, UK.

Digital Health
|June 10, 2024
PubMed
Summary

The juli digital app modestly reduced depression symptoms over 8 weeks compared to a placebo. This digital self-management tool may improve access to depression treatments for many.

Keywords:
AppsDigital healthbehaviour changedepressiondigital clinical trialsmotivationself-monitoring

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.9K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.2K

Related Experiment Videos

Last Updated: Jun 24, 2025

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

3.5K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.9K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.2K

Area of Science:

  • Digital health interventions
  • Mental health technology
  • Clinical psychology

Background:

  • Depression is a prevalent and debilitating mental health condition.
  • Digital applications offer potential to augment mental healthcare, especially for underserved populations.
  • The efficacy of digital self-management tools for depression requires rigorous evaluation.

Purpose of the Study:

  • To evaluate the efficacy of the juli digital self-management app for depression.
  • To compare the juli app's effectiveness against a limited attention-placebo control app.
  • To assess outcomes including symptom reduction, remission rates, and quality of life.

Main Methods:

  • A pragmatic, fully remote randomized controlled trial was conducted.
  • Participants (aged >18) with self-identified depression (PHQ-8 score >5) were randomized (1:1) to juli or a control app for 8 weeks.
  • Primary outcome: difference in Patient Health Questionnaire-8 (PHQ-8) scores at 8 weeks; secondary outcomes included remission and quality of life.

Main Results:

  • In the per-protocol analysis, the juli group showed a statistically significant greater reduction in PHQ-8 scores compared to the control group (p=0.045).
  • Remission and minimal clinically important difference were significantly more likely in the juli group (p<0.001 and p=0.018, respectively).
  • No significant differences were observed in health-related quality of life or worsening of depression between groups.

Conclusions:

  • The juli app demonstrated a small but statistically significant reduction in depression symptoms over 8 weeks compared to an attention-placebo control.
  • The findings suggest juli is a viable digital self-management tool that could enhance accessibility to evidence-based depression treatments.
  • Further research may explore long-term effects and effectiveness in diverse populations.